As our data demonstrated increased PPM1D expression in MCL cells, dual inhibition of PPM1D and MDM2 would be a logical approach to the treatment of MCL and, particularly, the aggressive form of this disease. This evidence concerns the gene PPM1D and mantle cell lymphoma.